A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- BeOne Medicines
- Study ID
- NCT06742996
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- B Cell Lymphoma
- Mantle Cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Sonrotoclax — DRUGAdministered orally
- Zanubrutinib — DRUGAdministered orally
- Placebo — DRUGAdministered orally
Study Details
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Key Dates
- Start date
- Mar 5, 2025
- Status verified
- Jun 2026
- Primary completion
- Aug 31, 2028
- Completion
- Mar 30, 2032
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: sonrotoclax plus zanubrutinibSonrotoclax and zanubrutinib will be administered in combination.
- Placebo Comparator: Arm B: placebo plus zanubrutinibPlacebo and zanubrutinib will be administered in combination.
Primary Outcome Measure
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) [ Time Frame: Approximately 41 months ]
Central Contacts
- Study Director1.877.828.5568
Locations (37)
Find similar trials in Birmingham, AL
By research site
University of Alabama At Birmingham Hospital· Birmingham, ALUniversity of Arizona Cancer Center· Tucson, AZUcsf Fresno· Fresno, CAKaiser Permanente Southern California· Irvine, CAYale University Yale Cancer Center· New Haven, CTMemorial Cancer Institute, Memorial Healthcare System· Pembroke Pines, FL
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaPHASE1/PHASE2 · Recruiting · City of Hope Medical Center · Duarte, California
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesPHASE2 · Recruiting · Fred Hutchinson Cancer Center · Seattle, Washington